Statistics: Sex difference analyses under scrutiny
Scientific research requires the use of appropriate methods and statistical analyses, otherwise results and interpretations can be flawed. How research outcomes differ by sex, for example, has historically been understudied, and only recently have policies been implemented to require such consideration in the design of a study (e.g., NIH, 2015).
Over two decades ago, the renowned biomedical statistician Doug Altman labeled methodological weaknesses a “scandal”, raising awareness of shortcomings related to the representativeness of research as well as inappropriate research designs and statistical analysis (Altman, 1994). These methodological weaknesses extend to research on sex differences: simply adding female cells, animals, or participants to experiments does not guarantee an improved understanding of this field of research. Rather, the experiments must also be correctly designed and analyzed appropriately to examine such differences. While guidance exists for proper analysis of sex differences, the frequency of errors in published research articles related to this topic has not been well understood (e.g., Beltz et al., 2019).
Now, in eLife, Yesenia Garcia-Sifuentes and Donna Maney of Emory University fill this gap by surveying the literature to examine whether the statistical analyses used in different research articles are appropriate to support conclusions of sex differences (Garcia-Sifuentes and Maney, 2021). Drawing from a previous study that surveyed articles studying mammals from nine biological disciplines, Garcia-Sifuentes and Maney sampled 147 articles that included both males and females and performed an analysis by sex (Woitowich et al., 2020).
Over half of the articles surveyed (83, or 56%) reported a sex difference. Garcia-Sifuentes and Maney examined the statistical methods used to analyze sex differences and found that over a quarter (24 out of 83) of these articles did not perform or report a statistical analysis supporting the claim of a sex difference. A factorial design with sex as a factor is an appropriate way to examine sex differences in response to treatment, by giving each sex each treatment option (such as a treatment or control diet; see Figure 1A). A slight majority of all articles (92, or 63%) used a factorial design. Within the articles using a factorial design, however, less than one third (27) applied and reported a method appropriate to test for sex differences (e.g., testing for an interaction between sex and the exposure, such as different diets; Figure 1B). Similarly, within articles that used a factorial design and concluded a sex-specific effect, less than one third (16 out of 53) used an appropriate analysis.
Notably, nearly half of the articles (24 out of 53) that concluded a sex-specific effect statistically tested the effect of treatment within each sex and compared the resulting statistical significance. In other words, when one sex had a statistically significant change and the other did not, the authors of the original studies concluded that a sex difference existed. This approach, which is sometimes called ‘differences in nominal significance’, or ‘DINS’ error (George et al., 2016), is invalid and has been found to occur for decades among several disciplines, including neuroscience (Nieuwenhuis et al., 2011), obesity and nutrition (Bland and Altman, 2015; George et al., 2016; Vorland et al., 2021), and more general areas (Gelman and Stern, 2006; Makin, 2019; Matthews and Altman, 1996; Sainani, 2010; Figure 1C).
This approach is invalid because testing within each sex separately inflates the probability of falsely concluding that a sex-specific effect is present compared to testing between them directly. Other inappropriate analyses that were identified in the survey included testing sex within treatment and ignoring control animals; not reporting results after claiming to do an appropriate analysis; or claiming an effect when the appropriate analysis was not statistically significant despite subscribing to ‘null hypothesis significance’ testing. Finally, when articles pooled the data of males and females together in their analysis, about half of them did not first test for a sex difference, potentially masking important differences.
The results of Garcia-Sifuentes and Maney highlight the need for thoughtful planning of study design, analysis, and communication to maximize our understanding and use of biological sex differences in practice. Although the survey does not quantify what proportion of this research comes to incorrect conclusions from using inappropriate statistical methods, which would require estimation procedures or reanalyzing the data, many of these studies’ conclusions may change if they were analyzed correctly. Misleading results divert our attention and resources, contributing to the larger problem of ‘waste’ in biomedical research, that is, the avoidable costs of research that does not contribute to our understanding of what is true because it is flawed, methodologically weak, or not clearly communicated (Glasziou and Chalmers, 2018).
What can the scientific enterprise do about this problem? The survey suggests that there may be a large variability in discipline-specific practices in the design, reporting, and analysis strategies to examine sex differences. Although larger surveys are needed to assess these more comprehensively, they may imply that education and support efforts could be targeted where they are most needed. Compelling scientists to publicly share their data can facilitate reanalysis when statistical errors are discovered – though the burden on researchers performing the reanalysis is not trivial. Partnering with statisticians in the design, analysis, and interpretation of research is perhaps the most effective means of prevention.
Scientific research often does not reflect the diversity of those who benefit from it. Even when it does, using methods that are inappropriate fails to support the progress toward equity. Surely this is nothing less than a scandal.
References
-
Analysis of sex differences in pre-clinical and clinical data setsNeuropsychopharmacology 44:2155–2158.https://doi.org/10.1038/s41386-019-0524-3
-
Best (but oft forgotten) practices: testing for treatment effects in randomized trials by separate analyses of changes from baseline in each group is a misleading approachThe American Journal of Clinical Nutrition 102:991–994.https://doi.org/10.3945/ajcn.115.119768
-
The difference between “significant” and “not significant” is not itself statistically significantThe American Statistician 60:328–331.https://doi.org/10.1198/000313006X152649
-
Erroneous analyses of interactions in neuroscience: a problem of significanceNature Neuroscience 14:1105–1107.https://doi.org/10.1038/nn.2886
-
WebsiteConsideration of Sex as a Biological Variable in NIH-funded ResearchAccessed October 13, 2021.
Article and author information
Author details
Publication history
- Version of Record published: November 2, 2021 (version 1)
Copyright
© 2021, Vorland
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,353
- views
-
- 238
- downloads
-
- 10
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Medicine
There is clear evidence that the sympathetic nervous system (SNS) mediates bone metabolism. Histological studies show abundant SNS innervation of the periosteum and bone marrow–these nerves consist of noradrenergic fibers that immunostain for tyrosine hydroxylase, dopamine beta-hydroxylase, or neuropeptide Y. Nonetheless, the brain sites that send efferent SNS outflow to the bone have not yet been characterized. Using pseudorabies (PRV) viral transneuronal tracing, we report, for the first time, the identification of central SNS outflow sites that innervate bone. We find that the central SNS outflow to bone originates from 87 brain nuclei, sub-nuclei, and regions of six brain divisions, namely the midbrain and pons, hypothalamus, hindbrain medulla, forebrain, cerebral cortex, and thalamus. We also find that certain sites, such as the raphe magnus (RMg) of the medulla and periaqueductal gray (PAG) of the midbrain, display greater degrees of PRV152 infection, suggesting that there is considerable site-specific variation in the levels of central SNS outflow to the bone. This comprehensive compendium illustrating the central coding and control of SNS efferent signals to bone should allow for a greater understanding of the neural regulation of bone metabolism, and importantly and of clinical relevance, mechanisms for central bone pain.
-
- Medicine
Rare early-onset lower urinary tract disorders include defects of functional maturation of the bladder. Current treatments do not target the primary pathobiology of these diseases. Some have a monogenic basis, such as urofacial, or Ochoa, syndrome (UFS). Here, the bladder does not empty fully because of incomplete relaxation of its outflow tract, and subsequent urosepsis can cause kidney failure. UFS is associated with biallelic variants of HPSE2, encoding heparanase-2. This protein is detected in pelvic ganglia, autonomic relay stations that innervate the bladder and control voiding. Bladder outflow tracts of Hpse2 mutant mice display impaired neurogenic relaxation. We hypothesized that HPSE2 gene transfer soon after birth would ameliorate this defect and explored an adeno-associated viral (AAV) vector-based approach. AAV9/HPSE2, carrying human HPSE2 driven by CAG, was administered intravenously into neonatal mice. In the third postnatal week, transgene transduction and expression were sought, and ex vivo myography was undertaken to measure bladder function. In mice administered AAV9/HPSE2, the viral genome was detected in pelvic ganglia. Human HPSE2 was expressed and heparanase-2 became detectable in pelvic ganglia of treated mutant mice. On autopsy, wild-type mice had empty bladders, whereas bladders were uniformly distended in mutant mice, a defect ameliorated by AAV9/HPSE2 treatment. Therapeutically, AAV9/HPSE2 significantly ameliorated impaired neurogenic relaxation of Hpse2 mutant bladder outflow tracts. Impaired neurogenic contractility of mutant detrusor smooth muscle was also significantly improved. These results constitute first steps towards curing UFS, a clinically devastating genetic disease featuring a bladder autonomic neuropathy.